publications-banner

Information about pipeline products

PublicationView

T-DXd
Gastric Cancer
Trastuzumab deruxtecan dosing in human epidermal growth factor receptor 2-positive gastric cancer: population pharmacokinetic modeling and exposure-response analysis
Yoshihara K, Kobayashi Y, Endo S, et al.
J Clin Pharmacol. 2023;63(11):1232-1243.
Edoxaban
Cardiovascular - AF Cardiovascular - VTE
Anticoagulant therapy and home blood pressure-associated risk for stroke/bleeding events in elderly patients with non-valvular atrial fibrillation: The sub-cohort study of ANAFIE registry
Kario K, Hasebe N, Okumura K, et al.
Hypertens Res. 2023;46:2572-2582.
Dato-DXd
Breast Cancer
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer
Bardia A, Jhaveri K, Kalinsky K, et al.
Future Oncol. 2024;20(8):423-436.
Edoxaban
Cardiovascular - AF
Causes of death in elderly patients with non-valvular atrial fibrillation - results from the ANAFIE registry
Yamashita T, Akao M, Atarashi H, et al.
Circ J. 2023;87(7):957-963.
Dato-DXd
Lung Cancer
First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01
Shimizu T, Sands J, Yoh K, et al.
J Clin Oncol. 2023;41(29):4678-4687.
T-DXd
Colorectal Cancer
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Yoshino T, Di Bartolomeo M, Raghav K, et al.
Nat Commun. 2023;14(1):3332.
Pexidartinib
Other/Multi
Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-year analysis of patient-reported outcomes and treatment strategies
Palmerini E, Healey JH, Bernthal NM, et al.
Oncologist. 2023;28(6):e425-e435.
Edoxaban
Cardiovascular - AF
Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients
Choi E-K, Choi J-I, Park H-S, et al.
J Arrhythm. 2023;39(4):546-555.
Dato-DXd
Lung Cancer
TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
Levy B, Felip E, Reck M, et al.
Future Oncol. 2023;19(21):1461-1472. 
HER3-DXd
Lung Cancer
HERTHENA-Lung01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
Yu HA, Yang J C-H, Hayashi H, et al.
Future Oncol. 2023;19(19):1319-1329.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer